Researchers at Adaptimmune and the University of  Pennsylvania announce the approval of an IND and opening for enrolment of the first ever study using engineered T cells to treat HIV

October 7th, 2009

Oxford, UK and Philadelphia, PA: 7 October 2009. Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine announce the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an engineered T cell receptor to treat HIV. The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.

See press release below:-

Adaptimmune Ltd Press Release – 07 Oct 2009

——————————————————————————————

•  The T Cell Processing Laboratory for the Generation of Engineered T cells Designed to Fight HIV Infection – Cell sorting.

Cell sorting – Patient cells are separated out to focus on the population best suited for targeting the HIV-infected cells.  They are then carefully expanded and prepared using the modified T cell receptor.

——————————————————————————————

• The T Cell Processing Laboratory for the Generation of Engineered T cells Designed to Fight HIV Infection – Final harvesting.

Final harvesting – after a period in culture, the patient’s cells are harvested, extensively tested and then re-administered to the patient.

Click below to download Press Release :-

Adaptimmune Ltd Press Release – 09 Nov 2008

Adaptimmune was officially founded on the 1st July 2008 with the remit of advancing the use of engineered T cell receptors in adoptive T cell therapy.